Nuvation Bio Inc. — Investor Relations & Filings

Nuvation Bio Inc. is a biopharmaceutical company dedicated to developing and commercializing novel therapies for oncology. The company focuses on addressing significant unmet needs in cancer treatment, particularly for difficult-to-treat malignancies where conventional therapies have limited efficacy. Its strategy involves creating a pipeline of differentiated therapeutic candidates that target critical pathways essential for cancer cell growth. Nuvation Bio aims to overcome drug resistance, improve outcomes over current standards of care, and reduce side effects to preserve patient quality of life. The company's portfolio includes Ibtrozi, an approved oral drug for the treatment of ROS1-positive non-small cell lung cancer (NSCLC), alongside other clinical-stage candidates.